Akebia Therapeutics Reports Data From Vafseo Outcomes In Center Experience Study At American Society Of Nephrology Kidney Week 2026 In Patients With Treated With Vadadustat
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease announced that U.S. Renal Care (USRC), the nation’s largest privately held
Akebia shared new study results about their kidney disease medicine at a big conference. When a company shows real patient data, it helps people understand if the treatment actually works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.